

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

DRAFT PROGRAMME AT A GLANCE

Updated 15/06/17

MONDAY 15TH JANUARY 2018

	Auditorium	Charter 1	Charter 2 & 3
9.00 – 10.30	Highlights of 2017 Basic Translational Early Disease Late Disease Professor Clare Isacke Professor Peter Schmid Professor Michael Gnant Dr Mark Verrill		
10.30 – 11.00	Key note lecture: Professor Marc Lippman Breast Cancer Research: Past and Future		
11.00 – 11.30	Coffee break	Coffee break	Coffee break
11.30 – 12.50	Metastatic Disease Managing ER+ Disease Professor Stephen Johnston Prognostics of metastatic disease Aleix Prat Evolution of resistance Adrian Harris	Ductal Carcinoma In Situ How should we address overdiagnosis and overtreatment of DCIS? Professor Laura Esserman How wide a margin do we need for DCIS? Professor Sarah Pinder Should radiotherapy be routinely recommended after wide local excision of DCIS?	Model systems PDX models Rob Clarke Organoid models Dr Mathew Garnett 3D in vitro modelling using material from Breast Cancer Now Tissue Bank Richard Grose

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

18.00 – 19.00: Drinks reception and poster viewing: Exhibition Hall

TUESDAY 16TH JANUARY 2018

	Auditorium	Charter 1	Charter 2 & 3
9 – 9.30	Key note lecture: Professor Jack Cuzick Breast Cancer prevention for the population at large		
9.30 – 11.10	Measuring and managing breast cancer risk Stratification to screening Fiona Gilbert Risk prediction for risk reduction Gareth Evans Findings from the Generations study Professor Tony Swerdlow Identifying genetic risk in the prevalent breast cancer population Nazneen Rahman	Triple Negative Breast Cancer Biology of the new targets Andrew Tutt Complexities of TNTs Chuck Perou Immunologic advances Giuseppe Curigliano	Breast Cancer Heterogeneity and evolution Genetic aspects Lucy Yates Experimental modelling of heterogeneity Rachael Natrajan Relevance to the histopathologist Fraser Symmans
11.10 – 11.40	Coffee break	Coffee break	Coffee break
11.40 – 13.00	New treatments and measuring their impact CDK4/6 inhibition Nick Turner New Selective Estrogen Receptor Downregulators (SERDS) Lesley-Ann Martin Liquid biopsies Jacqui Shaw	Lobular breast cancer Biologic aspects Steffi Oesterreich Genetic aspects Elly Sawyer Histologic dilemmas Ian Ellis Should lobular phenotype be considered when deciding treatment Michael Kerin	Communicating risk in the context of genomic testing

UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

15TH-16TH JANUARY 2018

MANCHESTER CENTRAL CONVENTION CENTRE

13.00 – 14.00	Lunch break	Industry Symposia	Industry symposia
14.00 – 14.30	Key note lecture: Chuck Perou Completion of the Cancer Genome Atlas		
14.30 – 16.10	<p>Biomarkers and prognostic profiling</p> <p>Lessons from molecular subtyping Clinical utility of molecular profiles Identifying who needs extended adjuvant ET Mutation-directed therapy</p> <p>Carlos Caldas Rob Stein Dan Hayes Fabrice Andre</p>	<p>Challenges of local management</p> <p>Management and follow up of patients presenting with breast cancer in axillary lymph nodes and occult breast primary</p> <p>Andreas Makris</p> <p>When is local surgery indicated in metastatic breast cancer? Nicola Roche</p> <p>What is the impact of MRI scanning on breast cancer treatment? Charlotte Coles</p> <p>Current and future indications for partial breast radiotherapy</p>	Clinical Trials Roadshow
16.10 – 16.40	Key note lecture: David Cameron Achievements of Breast Cancer Research in the UK		
16.40	CLOSING REMARKS		